Rocbrutinib

DB19445InvestigationalSmall molecule

Rocbrutinib is under investigation in clinical trial NCT05716087 (A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₄₂H₅₁N₉O₅ · 761.928 g/mol (avg)
Also known as: 2-Propenamide, N-[5-[[6-[2-(1,3,4,6,7,8-hexahydro-7,7-dimethyl-1-oxo-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3-(hydroxymethyl)-4-pyridinyl]-3,4-dihydro-4-methyl-3-oxo-2-pyrazinyl]amino]-2-[(2S)-2-methyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ph · N-[5-[[6-[2-(1,3,4,6,7,8-Hexahydro-7,7-dimethyl-1-oxo-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3-(hydroxymethyl)-4-pyridinyl]-3,4-dihydro-4-methyl-3-oxo-2-pyrazinyl]amino]-2-[(2S)-2-methyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]phenyl]-2-propena

Resolves to

Compound

UNIIKD68L3GRW2CAS2485861-07-0ChEMBLCHEMBL5314539ChEBI759240PubChem139416847

Structure

InChIKeyOYJVFTNYBWVQHA-SANMLTNESA-NSMILESC[C@H]1CN(CCN1C1=CC=C(NC2=NC(=CN(C)C2=O)C2=CC=NC(N3CCN4C5=C(CC(C)(C)C5)C=C4C3=O)=C2CO)C=C1NC(=O)C=C)C1CCOCC1

Targets

Q06187BTK

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rocbrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account